PhRMA Urges FDA To Set Non-Inferiority Margin For Skin Infection Drugs
Executive Summary
FDA should provide more specificity on the non-inferiority margin it expects clinical trials for acute bacterial skin and skin structure infection (ABSSSI) treatments to satisfy, pharmaceutical companies and infectious disease specialists say.
You may also be interested in...
Trius Antibiotic Tedizolid Hits Old, New And In-Between Endpoints
Tedizolid, a next-generation antibiotic from the same class as Pfizer’s Zyvox, has met all complicated skin infection endpoints for both a U.S. and European filing, and Trius plans submissions in second half 2013 and first half 2014, respectively. European partnering talks, meanwhile, have gained new intensity.
Antibiotic Development Incentives Could GAIN Support From Pipeline Survey
A survey showing improvement in the pipeline for new antibiotics could further the growing momentum for legislation that would create more development incentives.
Antibiotic Development Incentives Could GAIN Support From Pipeline Survey
A survey showing improvement in the pipeline for new antibiotics could further the growing momentum for legislation that would create more development incentives.